Ken Griffin Passage Bio, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Passage Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 7,700 shares of PASG stock, worth $5,082. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,700

Previous 8,300 7.23%

Holding current value

$5,082

Previous $6,000 16.67%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.64 - $1.0 $156,328 - $244,264	244,264 Added 154.34%	402,525 $281,000
Q2 2024 Aug 14, 2024	SELL	$0.79 - $1.58 $49,999 - $99,999	-63,291 Reduced 28.57%	158,261 $125,000
Q1 2024 May 15, 2024	SELL	$0.86 - $1.73 $77,538 - $155,978	-90,161 Reduced 28.92%	221,552 $299,000
Q4 2023 Feb 14, 2024	BUY	$0.6 - $1.01 $124,928 - $210,296	208,214 Added 201.17%	311,713 $314,000
Q3 2023 Nov 14, 2023	BUY	$0.66 - $1.01 $11,253 - $17,221	17,051 Added 19.72%	103,499 $68,000
Q2 2023 Aug 14, 2023	BUY	$0.82 - $1.19 $20,885 - $30,309	25,470 Added 41.77%	86,448 $81,000
Q1 2023 May 15, 2023	SELL	$0.96 - $1.88 $29,218 - $57,219	-30,436 Reduced 33.29%	60,978 $58,000
Q4 2022 Feb 14, 2023	SELL	$1.06 - $1.48 $116,880 - $163,192	-110,265 Reduced 54.67%	91,414 $126,000
Q3 2022 Nov 14, 2022	SELL	$1.22 - $2.48 $223,123 - $453,562	-182,888 Reduced 47.56%	201,679 $252,000
Q2 2022 Aug 15, 2022	BUY	$1.63 - $3.46 $223,924 - $475,324	137,377 Added 55.58%	384,567 $908,000
Q1 2022 May 16, 2022	BUY	$2.66 - $6.49 $457,719 - $1.12 Million	172,075 Added 229.08%	247,190 $767,000
Q4 2021 Feb 14, 2022	BUY	$6.24 - $10.2 $178,507 - $291,791	28,607 Added 61.51%	75,115 $476,000
Q3 2021 Nov 15, 2021	SELL	$9.73 - $15.52 $147,127 - $234,677	-15,121 Reduced 24.54%	46,508 $463,000
Q2 2021 Aug 16, 2021	SELL	$12.44 - $19.45 $7.64 Million - $11.9 Million	-614,058 Reduced 90.88%	61,629 $815,000
Q1 2021 May 17, 2021	BUY	$16.24 - $29.83 $11 Million - $20.2 Million	675,687 New	675,687 $11.8 Million
Q4 2020 Feb 16, 2021	SELL	$14.28 - $29.73 $266,250 - $554,315	-18,645 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$12.39 - $26.15 $53,252 - $112,392	-4,298 Reduced 18.73%	18,645 $245,000
Q2 2020 Aug 14, 2020	BUY	$14.59 - $36.07 $149,007 - $368,382	10,213 Added 80.23%	22,943 $627,000
Q1 2020 May 15, 2020	BUY	$8.86 - $22.2 $112,787 - $282,606	12,730 New	12,730 $200,000

Others Institutions Holding PASG

# of Institutions

Shares Held

38.7M

Call Options Held

7.7K

Put Options Held

View Full List

About Passage BIO, Inc.

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $35.9M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

More about PASG

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account